American Peptide has announced its new Total Peptide Management programme to help the pharmaceutical and life sciences industries bring new and innovative drugs to market faster
Said to be the first of its kind, Total Peptide Management offers a broad portfolio of peptides, value-added services, and expert consultation to support customer needs as their drug products move from discovery to development and commercialisation.
The programme is a customised service platform, which comprises a set of comprehensive services, including process development; scale-up production; analytical and process validation; stability studies; chemistry, manufacturing, and controls (CMC); drug master files (DMF) and regulatory support.
This platform complements the company's suite of advanced peptides to provide customers with efficient, high-quality and cost-effective peptide management solutions.
The Total Peptide Management programme leverages the experience and expertise of American Peptide to help customers properly select peptides and follow the correct procedures and compliance guidelines to streamline the drug development and manufacture process.
Additionally, the programme facilitates greater adherence to manufacturing standards and protocols at the company's manufacturing facilities.
It mandates application of GMP practices to non-GMP applications in the early phases of drug development to provide drug researchers with manufacturing processes that can be scaled up efficiently.
As part of the programme, the company provides innovative peptides in a timely and cost-effective manner to drug manufacturers.
The high-quality of these peptides helps manufacturers realise improved consistency, with higher yields and reliable product quality.
This helps companies looking to commercialise their product to significantly reduce their total operations cost, as well as speed time to market.
"The Total Peptide Management programme is a manifestation of our larger mission.
"We want to help our customers in their effort to pioneer innovative drug discovery and development solutions for preserving and improving human life," said Takahiro Ogata, president and COO of American Peptide.
"Moving forward in our mission, we will continue to demonstrate performance with integrity to deliver greater value to our customers, ensuring their ongoing success."
